Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ABOS

Acumen Pharmaceuticals Inc

May 02 • 04:00PM ET

3.48

Dollar change +0.23
Percentage change 7.08	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAS IBRN

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	27.33%	Shs Outstand	57.91M	Perf Week	9.09%
Market Cap	209.08M	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-0.21%	Shs Float	43.66M	Perf Month	-11.00%
Income	-52.37M	PEG	-	EPS next Q	-0.26	Inst Own	55.73%	Short Float	2.40%	Perf Quarter	11.90%
Sales	0.00M	P/S	-	EPS this Y	-23.66%	Inst Trans	4.20%	Short Ratio	3.16	Perf Half Y	86.10%
Book/sh	4.61	P/B	0.75	EPS next Y	-15.73%	ROA	-20.67%	Short Interest	1.05M	Perf Year	-5.95%
Cash/sh	4.05	P/C	0.86	EPS next 5Y	22.89%	ROE	-22.98%	52W Range	1.81 - 11.31	Perf YTD	-9.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-54.03%	ROI	-17.62%	52W High	-69.23%	Beta	0.19
Dividend TTM	-	Quick Ratio	19.01	Sales past 5Y	-28.84%	Gross Margin	-	52W Low	92.25%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	19.01	EPS Y/Y TTM	-2.55%	Oper. Margin	0.00%	RSI (14)	49.32	Volatility	5.14% 5.64%
Employees	52	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.80
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	9.53%	Payout	-	Rel Volume	0.69	Prev Close	3.25
Sales Surprise	-100.00%	EPS Surprise	-2.30%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	331.83K	Price	3.48
SMA20	0.80%	SMA50	-9.28%	SMA200	-15.88%	Trades		Volume	229,431	Change	7.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Initiated	Deutsche Bank	Buy	$8
Jul-20-23	Resumed	BofA Securities	Buy	$9 → $14
May-18-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jul-15-22	Initiated	BTIG Research	Buy	$15
Jun-30-22	Initiated	H.C. Wainwright	Buy	$15
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy	$16 → $14
Jul-26-21	Initiated	UBS	Buy	$27
Jul-26-21	Initiated	Stifel	Buy	$27
Jul-26-21	Initiated	Credit Suisse	Outperform	$26
Jul-26-21	Initiated	BofA Securities	Neutral	$20

Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-16-24 08:00AM	Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-08-24 05:38PM	13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
Apr-04-24 02:12PM	Acumen Pharmaceuticals Collaborates with Lonza For Alzheimers Treatment (Exec Edge)
08:00AM	Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease (GlobeNewswire)
08:38AM	Loading…
Apr-03-24 08:38AM	Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick (Zacks)
Mar-28-24 12:00PM	Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-27-24 09:46AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.33%
Mar-26-24 09:20PM	Q4 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -11.76%
11:52AM	ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights (GlobeNewswire)
Mar-21-24 10:41AM	Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-19-24 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 (GlobeNewswire)
Mar-18-24 10:31AM	15 Best Anti-Aging Foods for Youthful Skin (Insider Monkey)
04:00PM	Loading…
Mar-12-24 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days (GlobeNewswire)
Mar-08-24 08:50AM	Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-29-24 09:40AM	Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-21-24 08:00AM	Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-01-24 07:00AM	Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer (GlobeNewswire)
Jan-30-24 02:14PM	Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot (InvestorPlace)
Jan-24-24 01:58PM	3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom (InvestorPlace)
Jan-04-24 04:15PM	Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-23 08:53AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 11:08PM	Q3 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
10:54AM	Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update (GuruFocus.com)
09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
07:00AM	Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures (GlobeNewswire)
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-07-23 04:01PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire)
11:22AM	Loading…
11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 04:01PM	Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023 (GlobeNewswire) -5.02%
07:30AM	Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE Technology (GlobeNewswire)
Nov-02-23 04:00PM	Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference (GlobeNewswire)
Oct-27-23 09:25AM	Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease (GlobeNewswire) -24.84%
Oct-04-23 08:00AM	Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) (GlobeNewswire)
Sep-19-23 04:00PM	Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 10:21PM	Q2 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-01-23 04:00PM	Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023 (GlobeNewswire)
Jul-25-23 01:47PM	Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-18-23 10:31PM	Acumen Announces Pricing of Upsized $130 Million Public Offering (GlobeNewswire) -17.70%
11:32AM	Why Shares of Acumen Pharmaceuticals Are Down Tuesday (Motley Fool)
Jul-17-23 04:53PM	Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +54.78%
07:00AM	Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease (GlobeNewswire)
Jul-16-23 03:00AM	Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
02:00AM	Acumen's Alzheimer's drug passes initial safety test (Reuters)
Jul-03-23 05:13PM	12 Best NASDAQ Penny Stocks to Buy (Insider Monkey)
Jun-28-23 06:30AM	Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla (GlobeNewswire)
Jun-13-23 07:00AM	Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease During Featured Research Session at the Alzheimers Association International Conference (AAIC®) 2023 (GlobeNewswire) +13.49%
May-16-23 12:41PM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript (Insider Monkey) -9.52%
May-09-23 07:00AM	Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +18.14%
May-04-23 04:01PM	Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference (GlobeNewswire)
May-02-23 04:01PM	Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 (GlobeNewswire) -6.09%
Apr-09-23 08:57AM	Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the company (Simply Wall St.)
Mar-29-23 07:30AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-28-23 08:00AM	Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimers Disease (GlobeNewswire)
Mar-27-23 07:00AM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights (GlobeNewswire) +7.40%
Mar-22-23 04:01PM	Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days (GlobeNewswire) +5.15%
Mar-20-23 04:01PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023 (GlobeNewswire)
Mar-08-23 04:01PM	Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum (GlobeNewswire)
Feb-15-23 12:07PM	Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-13-23 08:00AM	Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A Oligomers in Patients with Early Alzheimers Disease (GlobeNewswire)
Jan-06-23 09:40AM	Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.55%
Jan-04-23 08:00AM	Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors (GlobeNewswire)
Dec-29-22 06:02AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript (Insider Monkey) +11.64%
Nov-14-22 04:01PM	Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -9.71%
Nov-09-22 04:01PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.45%
Nov-07-22 04:01PM	Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022 (GlobeNewswire)
Nov-01-22 08:00AM	Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimers Disease (GlobeNewswire)
Oct-24-22 08:00AM	Acumens ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Sep-08-22 12:44PM	We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-15-22 11:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights (GlobeNewswire)
Aug-08-22 04:15PM	Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-01-22 10:30AM	Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimers disease (GlobeNewswire) -8.09%
Jul-26-22 04:15PM	Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Jun-08-22 08:00AM	Hopeful week for insiders who might be regretting buying US$5.7m of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) stock earlier this year (Simply Wall St.)
May-16-22 10:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights (GlobeNewswire)
May-11-22 05:08PM	Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire) -14.21%
Apr-27-22 08:00AM	Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals New Approach to Treating Alzheimer's Disease (GlobeNewswire)
Apr-02-22 12:00AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript (Motley Fool)
Apr-01-22 05:01PM	We're Hopeful That Acumen Pharmaceuticals (NASDAQ:ABOS) Will Use Its Cash Wisely (Simply Wall St.)
Mar-28-22 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights (GlobeNewswire) -9.34%
Mar-16-22 04:15PM	Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 (GlobeNewswire) +11.72%
Dec-30-21 04:16AM	Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year (Simply Wall St.)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights (GlobeNewswire) -8.49%
Nov-08-21 08:00AM	Acumen Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-21 08:00AM	Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Oct-07-21 08:00AM	Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic A Oligomers for the Treatment of Early Alzheimers Disease (GlobeNewswire)
Oct-01-21 06:05AM	Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-16-21 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights (GlobeNewswire)
Jul-23-21 07:13PM	Landmark Infrastructure, CVRx See Activist Action (Barrons.com)
Jul-01-21 05:02PM	Krispy Kreme IPO Gains Nearly 24% in Busy Week for Deals (Barrons.com)
11:14AM	Acumen Pharmaceuticals shares soar 25% in trading debut (MarketWatch)
Jun-30-21 10:44PM	Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OConnell Daniel Joseph	President and CEO	Jan 19 '24	Sale	3.47	15,200	52,753	502,485	Jan 19 07:07 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 19 '24	Sale	3.48	8,933	31,048	108,867	Jan 19 07:06 PM
Zuga Matt	CFO & Chief Business Officer	Jan 18 '24	Sale	3.71	4,242	15,717	211,445	Jan 19 07:05 PM
Siemers Eric	Chief Medical Officer	Jan 18 '24	Sale	3.71	3,124	11,604	117,576	Jan 19 07:05 PM
Barton Russell	Chief Operating Officer	Jan 18 '24	Sale	3.73	2,833	10,555	96,867	Jan 19 07:04 PM
Ives Jeffrey L.	Director	Aug 17 '23	Option Exercise	0.75	41,949	31,519	39,149	Aug 18 06:31 PM
Ives Jeffrey L.	Director	Aug 17 '23	Sale	6.49	41,949	272,334	0	Aug 18 06:31 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 21 '23	Buy	7.75	5,161,290	39,999,998	13,043,179	Jul 25 04:30 PM

Open in Screener

CARA

Cara Therapeutics Inc

May 02 • 04:00PM ET

0.7722

Dollar change +0.0136
Percentage change 1.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CARA Cara Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO VHT FESM IWC CNBS

Index	RUT	P/E	-	EPS (ttm)	-2.19	Insider Own	15.00%	Shs Outstand	54.48M	Perf Week	10.31%
Market Cap	42.22M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	-1.01%	Shs Float	46.47M	Perf Month	-14.90%
Income	-118.51M	PEG	-	EPS next Q	-0.40	Inst Own	48.03%	Short Float	5.61%	Perf Quarter	37.67%
Sales	20.97M	P/S	2.01	EPS this Y	50.23%	Inst Trans	-0.35%	Short Ratio	4.21	Perf Half Y	-40.14%
Book/sh	1.05	P/B	0.74	EPS next Y	6.61%	ROA	-76.94%	Short Interest	2.61M	Perf Year	-81.12%
Cash/sh	1.85	P/C	0.42	EPS next 5Y	-	ROE	-109.80%	52W Range	0.50 - 4.67	Perf YTD	3.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.20%	ROI	-118.22%	52W High	-83.46%	Beta	0.81
Dividend TTM	-	Quick Ratio	4.43	Sales past 5Y	115.17%	Gross Margin	69.32%	52W Low	54.44%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	4.54	EPS Y/Y TTM	-37.39%	Oper. Margin	-579.43%	RSI (14)	50.91	Volatility	8.56% 9.36%
Employees	55	Debt/Eq	0.76	Sales Y/Y TTM	-49.92%	Profit Margin	-565.21%	Recom	1.40	Target Price	5.12
Option/Short	Yes / Yes	LT Debt/Eq	0.76	EPS Q/Q	-5.19%	Payout	-	Rel Volume	0.31	Prev Close	0.76
Sales Surprise	-68.12%	EPS Surprise	-32.29%	Sales Q/Q	-7.88%	Earnings	Mar 04 AMC	Avg Volume	619.17K	Price	0.77
SMA20	2.92%	SMA50	-7.33%	SMA200	-42.90%	Trades		Volume	192,930	Change	1.79%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $6
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight	$17 → $20
Nov-01-21	Resumed	Canaccord Genuity	Buy	$33
Aug-03-21	Initiated	JP Morgan	Neutral	$16
Apr-21-20	Reiterated	H.C. Wainwright	Buy	$30 → $33
Aug-12-19	Reiterated	H.C. Wainwright	Buy	$31 → $30
May-29-19	Reiterated	Laidlaw	Buy	$26 → $32
Feb-06-19	Resumed	Jefferies	Buy	$22
Jan-15-19	Initiated	BofA/Merrill	Neutral	$19
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy	$30
Aug-08-18	Reiterated	Stifel	Buy	$22 → $26
Jun-28-18	Reiterated	H.C. Wainwright	Buy	$24 → $26
Mar-12-18	Resumed	H.C. Wainwright	Buy	$22
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy	$27
Jun-30-17	Reiterated	Stifel	Buy	$24 → $20
Jun-30-17	Reiterated	Laidlaw	Buy	$35 → $30
Jun-30-17	Downgrade	Janney	Buy → Neutral
Mar-28-17	Reiterated	Laidlaw	Buy	$20 → $35

Show Previous Ratings

Apr-02-24 07:00AM	Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-07-24 07:00AM	Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 (GlobeNewswire) +6.05%
06:40AM	7 F-Rated Stocks to Sell in March 2024 (InvestorPlace)
Mar-05-24 09:07AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.98%
07:51AM	Q4 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:51PM	Loading…
Mar-04-24 08:51PM	CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.24%
05:10PM	Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Cara: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-12-24 04:01PM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 (GlobeNewswire)
Jan-22-24 10:19AM	Cara Layoffs 2024: What to Know About the Latest CARA Job Cuts (InvestorPlace)
07:00AM	Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 (GlobeNewswire)
Dec-18-23 07:00AM	Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis (GlobeNewswire) -48.85%
Nov-14-23 11:04AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.20%
08:48AM	Q3 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:00PM	Loading…
Nov-13-23 06:00PM	Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +12.38%
04:15PM	Cara: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-09-23 11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga) -6.72%
Nov-06-23 10:00AM	Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline (Zacks)
Nov-02-23 07:00AM	Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty (GlobeNewswire)
Oct-23-23 07:00AM	Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire)
Sep-25-23 07:00AM	Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients (GlobeNewswire)
Sep-05-23 07:00AM	Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.00%
Aug-10-23 02:53AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 05:54AM	Q2 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.75%
04:09PM	Cara: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:00AM	Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors (GlobeNewswire)
07:00AM	Loading…
Aug-02-23 07:00AM	Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-24-23 07:00AM	Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire)
Jun-14-23 01:37PM	The past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitable (Simply Wall St.)
Jun-13-23 06:30AM	3 Small-Cap Stocks to Sell in June Before They Crash and Burn (InvestorPlace)
Jun-02-23 06:46PM	Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Jun-01-23 07:00AM	Cara Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 06:34PM	7 Stocks With 1,000% Upside Potential (InvestorPlace)
May-25-23 06:40AM	Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark (Simply Wall St.) -6.55%
May-18-23 04:53PM	Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich or Broke. (InvestorPlace) -8.22%
02:00AM	Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus (PR Newswire)
May-16-23 11:02AM	Q1 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.23%
May-15-23 05:15PM	Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cara: Q1 Earnings Snapshot (AP Finance)
04:01PM	Cara Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 09:38AM	Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 65% (Simply Wall St.)
May-01-23 07:00AM	Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Apr-26-23 08:00PM	CARA: What does Argus have to say about CARA? (Argus Research)
Apr-10-23 07:00AM	Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-07-23 08:41AM	We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate (Simply Wall St.)
Mar-14-23 07:00AM	Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report (GlobeNewswire)
Mar-11-23 07:19AM	Things Look Grim For Cara Therapeutics, Inc. (NASDAQ:CARA) After Today's Downgrade (Simply Wall St.)
Mar-08-23 06:59AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 10:46AM	Metas stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market (MarketWatch) -33.23%
10:02AM	Q4 2022 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:43AM	Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss (Yahoo Finance Video)
08:05AM	Meta shares rise after new wave of layoffs, WeightWatchers stock makes gains after results and acquisition; Grindrs stock falls after profit drop (MarketWatch)
Mar-06-23 07:39PM	These 2 Stocks Are Plunging After Hours Monday (Motley Fool)
05:15PM	Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 10:00AM	Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-21-23 07:00AM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (GlobeNewswire)
Feb-15-23 05:11AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
Feb-08-23 05:00PM	Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine (GlobeNewswire)
Jan-17-23 07:00AM	Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023 (GlobeNewswire)
Jan-03-23 07:00AM	Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-22 05:53AM	Cara Therapeutics (NASDAQ:CARA shareholders incur further losses as stock declines 8.8% this week, taking three-year losses to 35% (Simply Wall St.) +8.61%
Nov-29-22 07:30AM	KemPharm Announces Appointment of Christopher Posner as New Independent Director (GlobeNewswire)
Nov-09-22 06:08AM	Cara Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-07-22 05:35PM	Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Cara Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 08:46AM	Why Cara Therapeutics (CARA) Might Surprise This Earnings Season (Zacks)
Nov-03-22 07:00AM	Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors (GlobeNewswire)
Nov-02-22 10:01AM	Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for (Zacks) -5.80%
07:00AM	Cara Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-22 10:00AM	Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-22 08:51AM	Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 67% (Simply Wall St.)
Oct-24-22 07:00AM	Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022 (GlobeNewswire)
Oct-18-22 09:55AM	Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High? (Zacks)
Oct-10-22 04:05PM	SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics (PR Newswire)
Sep-28-22 07:00AM	Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan (GlobeNewswire)
Sep-20-22 09:47AM	Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation (Simply Wall St.)
Sep-12-22 07:00AM	Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer (GlobeNewswire)
Sep-08-22 02:27PM	Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder (Benzinga)
08:15AM	Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress (GlobeNewswire)
Sep-06-22 07:00AM	Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 07:00AM	Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022 (GlobeNewswire)
Aug-22-22 07:00AM	Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress (GlobeNewswire)
Aug-19-22 01:00AM	Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022 (GlobeNewswire)
Aug-08-22 05:15PM	Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Cara Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 08:48AM	Should You Buy Cara Therapeutics (CARA) Ahead of Earnings? (Zacks) +12.26%
Aug-03-22 07:00AM	Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +7.02%
Aug-01-22 04:01PM	Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022 (GlobeNewswire) -5.72%
Jul-28-22 09:14AM	10 Medical Marijuana Stocks to Buy Now (Insider Monkey)
Jul-22-22 06:39AM	Investors in Cara Therapeutics (NASDAQ:CARA) have unfortunately lost 56% over the last three years (Simply Wall St.)
Jun-30-22 10:19AM	Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder (Benzinga)
07:00AM	Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica (GlobeNewswire)
Jun-06-22 11:46AM	10 Best CBD Stocks To Invest In (Insider Monkey)
May-23-22 07:04AM	What Type Of Shareholders Own The Most Number of Cara Therapeutics, Inc. (NASDAQ:CARA) Shares? (Simply Wall St.)
May-17-22 07:00AM	Cara Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.18%

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Terrillion Scott	SEC'Y; CHIEF COMPLIANCE & G.C.	Apr 05 '24	Sale	0.83	2,753	2,285	88,247	Apr 09 04:21 PM
Goncalves Joana	CHIEF MEDICAL OFFICER	Apr 05 '24	Sale	0.83	2,753	2,285	53,365	Apr 09 04:22 PM
Posner Christopher	PRESIDENT AND CEO	Feb 29 '24	Sale	0.89	5,834	5,192	180,521	Mar 04 04:19 PM
Goncalves Joana	CHIEF MEDICAL OFFICER	Feb 29 '24	Sale	0.89	3,293	2,931	56,118	Mar 04 04:13 PM
Terrillion Scott	SEC'Y; CHIEF COMPLIANCE & G.C.	Feb 29 '24	Sale	0.89	3,293	2,931	91,000	Mar 04 04:24 PM
Posner Christopher	PRESIDENT AND CEO	Feb 08 '24	Sale	0.53	35,575	18,855	186,355	Feb 12 05:10 PM
Posner Christopher	PRESIDENT AND CEO	Feb 01 '24	Sale	0.55	4,981	2,740	221,930	Feb 05 04:26 PM
Posner Christopher	President and CEO	Nov 02 '23	Sale	1.22	3,796	4,631	164,411	Nov 03 04:37 PM
Posner Christopher	President and CEO	Aug 03 '23	Sale	3.07	4,307	13,222	168,207	Aug 04 05:21 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Jun 23 '23	Sale	3.51	2,993	10,505	153,747	Jun 27 04:08 PM
Goncalves Joana	Chief Medical Officer	Jun 23 '23	Sale	3.51	2,723	9,558	53,681	Jun 27 04:07 PM
Terrillion Scott	Sec'y; Chief Compliance & G.C.	Jun 23 '23	Sale	3.51	2,483	8,715	88,563	Jun 27 04:09 PM
Posner Christopher	President and CEO	May 05 '23	Sale	4.40	3,869	17,024	172,514	May 09 04:22 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ABOS

Acumen Pharmaceuticals Inc

CARA

Cara Therapeutics Inc

Upgrade your FINVIZ experience